Calistoga Pharmaceuticals, Inc. is the leader in developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases.
The PI3K pathway is a critical cellular pathway involved in cell survival and immune cell activation. Calistoga Pharmaceuticals' small-molecule therapeutic candidates inhibit specific isoforms of the PI3K pathway, providing a targeted treatment approach designed to maximize clinical outcome and limit unwanted side effects.
Calistoga Pharmaceuticals' lead product, CAL-101, an oral delta-isoform selective PI3K inhibitor, has demonstrated promising clinical responses in patients with B-cell malignancies and is currently being evaluated in multiple clinical trials. In addition to CAL-101, Calistoga Pharmaceuticals' product development pipeline includes other selective PI3K inhibitors in early preclinical development or ready for initial clinical trials in patients with cancer or inflammatory diseases.
Past Team (4)Update
Funding Rounds (4) - $92MUpdate
Early stage healthcare
Alta Partners is a leading venture capital firm in life sciences, funding over 130 companies in...
Amgen engages in the development of human therapeutic products in supportive of cancer care,...
Founded in 1991, Frazier Healthcare Ventures is one of the leading providers of venture and...
Three Arch Partners was formed in 1993 to provide young companies with access to relevant...
2101 4th Avenue, Suite 1960
Seattle, WA 98121